NCT06086288View on ClinicalTrials.gov

Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Merkel Cell Carcinoma
Interventions
DRUG

Pembrolizumab, Etoposide, Cisplatin or Carboplatin

Induction Phase (4 cycles, 1Cycle=3W): Pembrolizumab 200 mg + Etoposide + Cisplatin or Carboplatin; Maintenance Phase (16 Cycles, 1Cycle=6W): Pembrolizumab 400 mg

Trial Locations (3)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Unknown

AOUS Policlinico Le Scotte, Siena

Azienda Ospedaliera Universitaria Integrata (AOUI), Verona

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER